Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering

Praxis Precision Medicines (NASDAQ: PRAX) priced an underwritten public offering of 2,212,000 common shares at $260.00 per share, with gross proceeds of about $575 million before underwriting discounts and expenses.

Rhea-AI Summary

Praxis Precision Medicines (NASDAQ: PRAX) priced an underwritten public offering of 2,212,000 common shares at $260.00 per share, with gross proceeds of about $575 million before underwriting discounts and expenses. The company granted underwriters a 30‑day option to purchase up to 331,800 additional shares (15% overallotment). The offering is expected to close on or about January 8, 2026, subject to customary closing conditions and market conditions. The offering is being made from a shelf registration that became effective December 23, 2024; a preliminary prospectus supplement was filed January 6, 2026.

Positive

• Gross proceeds of approximately $575 million
• Offered 2,212,000 shares at $260.00 per share
• Underwriters granted 331,800-share 30-day option (15% overallotment)

Negative

• Net proceeds will be reduced by underwriting discounts and offering expenses
• Closing is subject to market conditions and customary closing conditions

Argus Jan 7 session

+7.23% close to close Open Argus

Details

News Market Reaction – PRAX

On Jan 7, the first trading day after this news, PRAX closed 7.23% above the previous close.

Data tracked by StockTitan Argus for the Jan 7 session.

Market Context

On Jan 7, the first trading day after this news, the stock closed 7.2% above the previous close. A s...

Analysis

On Jan 7, the first trading day after this news, the stock closed 7.2% above the previous close. A strong positive reaction aligns with prior PRAX behavior, where even equity offerings followed powerful moves after favorable clinical and regulatory milestones. Investors had previously rewarded capital raises that extended runway ahead of multiple NDA plans. However, repeat large offerings can increase dilution risk, and history shows sentiment can reverse once financing momentum fades. Sustainability would likely depend on continued execution against late-stage neurology programs and clear visibility into future capital needs.

Key Figures

Offering size: $575 million Shares offered: 2,212,000 shares Offering price: $260.00 per share +5 more

Offering size

$575 million

Expected gross proceeds from January 2026 public offering

Shares offered

2,212,000 shares

Common stock in January 2026 underwritten public offering

Offering price

$260.00 per share

Public offering price for common stock

Underwriters’ option

331,800 shares

Additional shares under 30-day option

Option period

30 days

Underwriters’ option window to buy additional shares

Expected close date

January 8, 2026

Anticipated closing of the public offering

Effective registration date

December 23, 2024

Date registration statement became effective

Prospectus filing date

January 6, 2026

Preliminary prospectus supplement filing with SEC

Historical Context

5 past events · Latest: Dec 29

5 events

1. Dec 29

   Regulatory designation

   24h Move

   +13.3%

   Breakthrough Therapy Designation for ulixacaltamide and NDA planning.

2. Dec 11

   Regulatory meeting

   24h Move

   +2.2%

   FDA cleared early 2026 NDA filing for relutrigine in DEEs.

3. Dec 09

   Trial design update

   24h Move

   -4.7%

   FDA alignment on simplified single-arm EMBRAVE3 design for elsunersen.

4. Dec 08

   Clinical data update

   24h Move

   +9.3%

   Strong EMBOLD and RADIANT clinical data across epilepsy programs.

5. Dec 04

   Topline trial results

   24h Move

   +3.0%

   Positive registrational EMBOLD topline results and early stop for efficacy.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

underwritten public offering, gross proceeds, book-running managers, prospectus supplement, +2 more

6 terms

underwritten public offering financial

"announced the pricing of its underwritten public offering of 2,212,000 shares"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

gross proceeds financial

"The gross proceeds from the offering are expected to be approximately $575 million"

The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.

book-running managers financial

"Piper Sandler, TD Cowen, Guggenheim Securities and Truist Securities are acting as joint book-running managers"

Book-running managers are the main banks or financial firms that organize and oversee a company's sale of new stocks or bonds. They help set the price, decide how many to sell, and coordinate the process to make sure everything runs smoothly. Their role is important because they guide the company through the complex process of raising money from investors.

prospectus supplement regulatory

"A preliminary prospectus supplement related to the offering was filed with the SEC"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

base prospectus regulatory

"including a base prospectus, that was filed by Praxis with the Securities and Exchange Commission"

A base prospectus is a detailed document that provides essential information about a financial offering, such as a bond or share issue. It acts like a comprehensive guide for investors, explaining what the investment involves, the risks involved, and how the process works. This helps investors make informed decisions before committing their money.

Securities and Exchange Commission regulatory

"was filed by Praxis with the Securities and Exchange Commission (SEC)"

A national government agency that enforces rules for buying, selling and disclosing information about stocks and other investments, acting like a referee and scorekeeper for financial markets. It requires companies to share clear, regular financial and business information and investigates fraud or rule-breaking, which matters to investors because those rules and disclosures help ensure fair prices, reduce hidden risks and make it easier to compare investment choices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the pricing of its underwritten public offering of 2,212,000 shares of its common stock at a public offering price per share of $260.00. The gross proceeds from the offering are expected to be approximately $575 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Praxis. All shares in the offering are being offered by Praxis. In addition, Praxis has granted the underwriters a 30-day option to purchase up to 331,800 additional shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about January 8, 2026, subject to market conditions and the satisfaction of customary closing conditions.

Piper Sandler, TD Cowen, Guggenheim Securities and Truist Securities are acting as joint book-running managers for the offering. LifeSci Capital, Baird and Oppenheimer & Co. are acting as lead managers for the offering. H.C. Wainwright & Co. and Needham & Company are acting as co-managers for the offering.

The offering is being made pursuant to a shelf registration statement on Form S-3ASR, including a base prospectus, that was filed by Praxis with the Securities and Exchange Commission (SEC) and automatically became effective upon filing on December 23, 2024. A preliminary prospectus supplement related to the offering was filed with the SEC on January 6, 2026. The final prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying base prospectus relating to the offering, when available, may be obtained from: Piper Sandler & Co., 350 North 5^th Street, Suite 1000, Minneapolis, MN 55401, Attention: Prospectus Department, by telephone at (800) 747-3924, or by email at prospectus@psc.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or Truist Securities, Inc., Attention: Equity Capital Markets, 740 Battery Ave SE, Atlanta, Georgia 30339, by telephone at (800) 685-4786 or by email at truistsecurities.prospectus@truist.com. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including express or implied statements regarding Praxis’ future expectations, plans and prospects, including, without limitation, statements regarding the timing of the completion, and anticipated gross proceeds, of the offering, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “endeavor,” “estimate,” “expect,” “anticipate,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will” or “would” and similar expressions that constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995.

The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation, risks related to market conditions and other risks described in Praxis’ Annual Report on Form 10-K for the year ended December 31, 2024, its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 and other filings made with the SEC. Although Praxis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on information and factors currently known by Praxis. As a result, you are cautioned not to rely on these forward-looking statements. Any forward-looking statement made in this press release speaks only as of the date on which it is made. Praxis undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

Investor Contact:
Praxis Precision Medicines
investors@praxismedicines.com
857-702-9452

Media Contact:
Dan Ferry
LifeSci Advisors
Daniel@lifesciadvisors.com
617-430-7576

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did Praxis (PRAX) offer in the January 2026 public offering?

Praxis offered 2,212,000 common shares in the offering.

What was the public offering price per share for PRAX on January 7, 2026?

The public offering price was $260.00 per share.

How much gross capital will Praxis (PRAX) raise from the offering?

Gross proceeds are expected to be approximately $575 million before fees and expenses.

Does the PRAX offering include an overallotment option and how large is it?

Yes; underwriters have a 30‑day option to buy up to 331,800 additional shares (15% overallotment).

When is the PRAX public offering expected to close?

The offering is expected to close on or about January 8, 2026, subject to customary conditions.

Where can investors find the final prospectus supplement for the PRAX offering?

The final prospectus supplement will be filed with the SEC and available at www.sec.gov.